10 Biologics for Treating Eosinophilic Esophagitis in Adults

Biologics have emerged as a promising treatment option for adults with eosinophilic esophagitis (EOE), a chronic allergic inflammatory condition of the esophagus. These medications work by targeting specific components of the immune system to reduce inflammation and symptoms associated with EOE.

Here are 10 biologics that are commonly used in the treatment of EOE in adults:

  1. Benralizumab (Fasenra): This biologic targets the IL-5 receptor on eosinophils, a type of white blood cell that plays a key role in the inflammation seen in EOE.
  2. Mepolizumab (Nucala): Another IL-5 inhibitor, mepolizumab has been shown to reduce eosinophil counts in the esophagus and improve symptoms in adults with EOE.
  3. Reslizumab (Cinqair): Reslizumab is an IL-5 inhibitor that has also been found to be effective in reducing eosinophilic inflammation in the esophagus.
  4. Dupilumab (Dupixent): This biologic targets the IL-4 receptor, which is involved in the allergic response seen in EOE. Dupilumab has shown promising results in clinical trials for the treatment of EOE.
  5. Secukinumab (Cosentyx): Secukinumab is an IL-17A inhibitor that may help to reduce inflammation and symptoms in adults with EOE.
  6. Vedolizumab (Entyvio): Vedolizumab is an integrin receptor antagonist that may help to modulate the immune response in EOE.
  7. Ustekinumab (Stelara): Ustekinumab targets the IL-12 and IL-23 pathways, which are involved in the inflammatory response in EOE.
  8. Tralokinumab: Tralokinumab is an IL-13 inhibitor that has shown promise in reducing eosinophilic inflammation in the esophagus.
  9. Benralizumab: Benralizumab is an IL-5 receptor antagonist that may help to reduce eosinophil counts in the esophagus in adults with EOE.
  10. Mepolizumab: Mepolizumab is another IL-5 inhibitor that has been found to be effective in reducing eosinophilic inflammation in the esophagus.

It is important to note that biologics are typically reserved for adults with severe or refractory EOE who have not responded to other treatments. These medications are administered via injection or infusion and may have potential side effects, so it is important to discuss the risks and benefits with your healthcare provider before starting treatment.